NASDAQ:VCELVericel Stock Price, Forecast & News

Vericel's stock was trading at $12.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VCEL stock has increased by 23.3% and is now trading at $14.89. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vericel.

Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Vericel.

Vericel Corp (NASDAQ:VCEL) released its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.02. The biotechnology company earned $26.70 million during the quarter, compared to analyst estimates of $26.23 million. Vericel had a negative net margin of 9.39% and a positive return on equity of 5.87%. The business's revenue was up 22.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.07) earnings per share. View Vericel's earnings history.

5 brokers have issued 1 year price objectives for Vericel's stock. Their forecasts range from $21.00 to $32.00. On average, they expect Vericel's share price to reach $24.25 in the next twelve months. This suggests a possible upside of 62.9% from the stock's current price. View analysts' price targets for Vericel.

News articles about VCEL stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vericel earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Vericel.

Some companies that are related to Vericel include Denali Therapeutics (DNLI), Immunovant (IMVT), Twist Bioscience (TWST), Bill.com (RVMD), Alector (ALEC), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Adverum Biotechnologies (ADVM), Mesoblast (MESO), Beam Therapeutics (BEAM), Sorrento Therapeutics (SRNE), I-Mab (BDTX), Legend Biotech (PCVX), Regenxbio (RGNX) and NanoString Technologies (NSTG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Momo (MOMO), Novavax (NVAX), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), NVIDIA (NVDA), Verastem (VSTM), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCEL stock can currently be purchased for approximately $14.89.

Vericel has a market capitalization of $671.69 million and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Vericel employs 216 workers across the globe.

The official website for Vericel is www.vcel.com.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]